A Letter from The Office of the Vice Chancellor for Research

More documents

Recommendations

Info

OVCR Annual ReportFiscal Year 2011Technology Management & Intellectual PropertyNatriuretic Peptide-Mediated Imaging and/or Treatment of AtheroscleroticPlaqueThis invention includes a functionalized peptide that preferentially binds to unstable plaque.Imaging of unstable plaque may identify areas of imminent plaque rupture so that correctiveaction can be taken before a catastrophic event occurs. A large corporate partner is exploring aresearch partnership using this technology. Primary Investigator: Pamela Woodard, Radiology.Novel Virus Discovery ProgramSeveral nucleic acid fragments of novel viruses have been discovered in disease samples ofunknown etiology. Over the next few years, the study of these novel fragments should result innearly complete genome and protein characterizations of several novel human viral pathogens.The novel sequences may be used in diagnostic tests or vaccines production. This technology isexpanding into other departments and is resulting in new molecular approaches to discoveries.Primary Investigator: Herbert Virgin, David Wang, Pathology.Dnmt3a, Novel Prognostic Markers for Acute Myeloid LeukemiaTwenty two percent of AML patients have a mutation in the Dnmt3a gene. These novelmutations predict which form of AML will require intensive therapy for best outcomes.Several companies are exploring this marker for licensing and implementation onto adiagnostic platform. Primary Investigator: Timothy Ley, Internal Medicine; John Dipersio,Internal Medicine; Richard Wilson, Genetics; Li Ding, Genetics; and Elaine Mardis,Genetics.The Novel Effects of NAD-Related Compounds (Nicotinamide, NicotinamideMononucleotide & NAD) on Blood Glucose LevelsNMN has been shown to be an effective molecule to regulate blood glucose levels in animalmodels. A US patent has been issued for this technology. Currently a large sponsored researchagreement is in place with a small molecule manufacturing company to test NMN on a widescalefor blood glucose regulation. Primary Investigator: Shin-ichiro Imai, Molecular Biology.Novel Biomarkers for the Early Detection of Renal Cell CarcinomaTwo novel biomarkers can be detected in urine indicating renal cell carcinoma via non-invasivetechniques. The technology has developed from west blotting techniques to quantitative ELISAassays making this technology more attractive to and compatible with diagnostic companies’clinical platforms. Although a few start-up companies have evaluated this technology, it shouldbe ready for licensing to large corporations early in 2012. Primary Investigators: Evan Kharasch,Anesthesiology, and Jeremiah Morrissey, Anesthesiology.Effective Anti-integrin Antitumor Reagent for ChrondrosarcomaChondrosarcoma is a difficult musculoskeletal tumor to treat. Chemotherapy is only somewhateffective in mesenchymal chondrosarcoma and is of uncertain value in dedifferentiatedchondrosarcoma. Surgical excision is the only tumor treatment, but it leads to severe disabilitywith high rate of local recurrence, often at a higher grade, and can thus be life threatening.47
OVCR Annual ReportFiscal Year 2011Technology Management & Intellectual PropertyRadiation and adjuvant therapy are not effective in differentiated chondrosarcoma. Moreeffective antitumor reagents for chondrosarcoma are needed. The present invention utilizes ananti-integrin reagent which has chondrosarcoma tumor cell killing activity in vitro. Promisinganimal data indicates that this is also true in vivo.Primary Investigator: Linda Sandell,Orthopaedic SurgeryAnticonvulsant and Anxiolytic Lactam and Thiolactam DerivativesThis invention relates to lactam and thiolactam derivatives having useful anticonvulsant andanxiolytic activity, pharmaceutical compositions containing these compounds and therapeuticapplications using such compositions. Convulsant seizures occur in various chronic centralnervous system (CNS) disorders, particularly epilepsies. These seizures are generally correlatedwith abnormal and excessive EEG (electroencephalogram) discharges. A variety of drugs havebeen used for treatment of these seizures. The compounds covered under this patentsignificantly enhance GABA neuronal inhibition and are more active anticonvulsant andanxiolytic agents than prior art lactones and thiolactones. Further, these lactams and thiolactamshave been found to have relatively low toxicity and low sedative activity. Primary Investigator:Doug Covey, Developmental BiologyMethods of Prevention and Treatment of Ischemic DamageThe present invention in various embodiments provides methods of treating stroke andconferring protection on a population of cells associated with ischemia in a subject following anischemic event, comprising: (a) providing an estrogen compound; and (b) administering theeffective amount of the compound over a course that includes at least one dose within a timethat is effectively proximate to the ischemic event, so as to confer protection on the populationof cells. Novel methods are provided for the delivery of an estrogen compound. Examples ofischemic events treatable according to the invention are cerebrovascular disease or stroke,subarachnoid subhemorrhage, myocardial infarct, surgery and trauma. A method of treatingischemic damage utilizing hormones that are non-sex hormones is also provided. A method oftreating stroke with ent-17.beta.-estradiol, and a method of synthesis, and compounds producedfrom the synthesis are provided. Primary Investigator: Doug Covey, Developmental BiologyNeuroactive 13, 24-Cyclo-18, 21-Dinorcholanes and Structurally RelatedPentacyclic SteroidsThe present invention is directed to novel pentacyclic steroids and novel pentacyclic D-homosteroids that have utility as anesthetics and in the treatment of disorders relating to GABAfunction and activity. In addition to anesthetic properties, neuroactive steroids may be used totreat disorders related to GABA function. For example, neuroactive steroids may be used assedative-hypnotics e.g. insomnia, mood disorders, convulsive disorders, anxiety, or symptoms ofethanol withdrawal. These agents act by enhancing GABA.sub.A receptor desensitization anddisplay different degrees of enantioselectivity. These compounds may be useful as memoryenhancers and in reversing the anesthetic effects of compounds that potentiate GABA atGABA.sub.A receptors. Primary Investigator: Doug Covey, Developmental Biology48
Page 1 and 2: LEADERSHIPSUPPORTSERVICEINTEGRITYIN
Page 3 and 4: Private providers of research fundi
Page 5 and 6: Clinical Trials - Industry Sponsore
Page 7 and 8: OVCR Annual ReportFiscal Year 2011S
Page 43 and 44: OVCR Annual ReportFiscal Year 2011T
Page 51: OVCR Annual ReportFiscal Year 2011T
Page 73 and 74: OVCR Annual ReportFiscal Year 2011C
Page 99: OVCR Annual ReportFiscal Year 2011S

A Letter from The Office of the Vice Chancellor for Research

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?